March 7, 2017 / 9:13 PM / 5 months ago

BRIEF-Lion Biotechnologies reports Q4 GAAP loss per share of $0.25

March 7 (Reuters) - Lion Biotechnologies Inc

* Lion Biotechnologies reports fourth quarter and full-year 2016 financial results and provides corporate update

* Q4 non-GAAP loss per share $0.20 excluding items

* Q4 GAAP loss per share $0.25

* Lion Biotechnologies says it is initiating two phase 2 trials for LN-145 for treatment of head and neck and cervical cancers in 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below